Citius Pharmaceuticals, Inc. — Form 8-K

Citius Pharmaceuticals reported $7.1M in LYMPHIR revenue for the nine months ended June 30, 2026 (vs. $0 prior year), with the product now available at 44 institutions. The company holds $17.0M in cash as of June 30, 2026, bolstered by $4.5M net proceeds from an April 2026 registered direct offering, $9.7M from warrant exercises, and $10.0M from the first tranche of a $25M term loan to majority-owned subsidiary Citius Oncology. Institutional vial orders increased 31%; new institutions ordering rose 80%. However, nine-month net loss applicable to common stockholders was $38.3M ($1.64 per share), including a non-recurring $19.7M contract cancellation charge, though losses per share improved year-over-year ($3.27 prior year). Expanded commercial team of 29 professionals deployed nationwide; Phase 1 data showed encouraging activity in combination therapies (86% ORR in CAR-T pre-treatment, 24% ORR with pembrolizumab).